ImmuPharma (LON:IMM) Trading Down 21.1% - Here's What Happened

Key Points

• ImmuPharma plc's stock price fell by 21.1%, closing at GBX 11.76 ($0.16), after trading as low as GBX 10.80 ($0.15).
• The company reported a net margin of 3,519.56% alongside a negative return on equity of 131.41%, with forecasted earnings per share projected at approximately -339.00 for the current fiscal year.
• ImmuPharma specializes in developing peptide-based therapeutics for autoimmune diseases, with its lead program being P140 (Lupuzor™), targeting the treatment of Lupus.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) were down 21.1% during mid-day trading on Wednesday . The company traded as low as GBX 10.80 ($0.15) and last traded at GBX 11.76 ($0.16). Approximately 45,915,910 shares traded hands during trading, an increase of 438% from the average daily volume of 8,530,393 shares. The stock had previously closed at GBX 14.90 ($0.20).

ImmuPharma Stock Performance

The company has a market capitalization of £60.72 million, a price-to-earnings ratio of -1,365.17 and a beta of 1.53. The firm's 50-day simple moving average is GBX 3.87 and its 200-day simple moving average is GBX 3.15.

ImmuPharma (LON:IMM - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Equities research analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.